Phase I
Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).
With growing concerns about the rise of drug resistant bacteria, multiple companies are developing new forms of antimicrobials to take on serious health concerns.
The 2018 American Association for Cancer Research (AACR) is being held in Chicago. Here’s a roundup of some of today’s company news.
It seems inevitable that as marijuana becomes more broadly legal in the U.S., that the biopharma industry and larger corporations will take an interest.
Fueled by positive Phase I and Phase I/II results from an open-label extension (OLE) study of RNAi therapeutic givosiran, as well as an ongoing Phase III trial, Cambridge, Mass.-based Alnylam said it is eying a possible New Drug Application by the end of the year.
Pfizer Inc. has dosed its first patient in a Phase Ib clinical trial of PF-06939926 for Duchenne muscular dystrophy (DMD). At the moment, the only approved drug is Sarepta Therapeutics’ Exondys 51 (eteplirsen).
One month after three patients who developed adverse reactions following injections of an unauthorized herpes vaccine filed a lawsuit against Rational Vaccines, the U.S. Food and Drug Administration has launched a criminal investigation into the matter.
Cellectis has found some sure financial footing that will support its efforts through the remainder of the year. The company secured $163.7 million in an initial public offering to develop CART-T products.
Danish pharma giant Novo Nordisk tied up a sickle cell and beta-thalassemia program in a $400 million deal with Ohio-based EpiDestiny.
A company focused on aging-related ailments is looking to infuse new life into its coffers through an initial public offering. Unity Biotechnology is seeking to raise $85 million in the IPO as it takes its lead candidate into the clinic later this year.
PRESS RELEASES